UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir

Antimicrobial agents and chemotherapy, 2015-11, Vol.59 (11), p.6922-6929

2015

Volltextzugriff (PDF)

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons

Antimicrobial agents and chemotherapy, 2016-05, Vol.60 (5), p.2954-2964

2016

Volltextzugriff (PDF)

Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons

Antimicrobial agents and chemotherapy, 2017-07, Vol.61 (7)

2017

Volltextzugriff (PDF)

Functional Analysis of the Chemokine Receptor CCR3 on Airway Epithelial Cells

Journal of Immunology, 2006-09, Vol.177 (5), p.3344-3354

2006

Volltextzugriff (PDF)

Regulation of eotaxin gene expression by TNF-alpha and IL-4 through mRNA stabilization: involvement of the RNA-binding protein HuR

The Journal of immunology (1950), 2003-10, Vol.171 (8), p.4369-4378

2003

Volltextzugriff (PDF)

A Retrospective Study Investigating the Incidence and Predisposing Factors of Hospital-Acquired Anemia

Anemia, 2014-01, Vol.2014 (2014), p.634582-6

2014

Volltextzugriff (PDF)

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors

Antiviral research, 2009-11, Vol.84 (2), p.178-184

2009

Volltextzugriff (PDF)

Abstract #901: Leydig Cell Ovarian Tumor

Endocrine practice, 2015-05, Vol.21, p.177-178

2015

Volltextzugriff (PDF)

Mother and child constructions of risk in outdoor play

Leisure studies, 2014-11, Vol.33 (6), p.644-657

2014

Volltextzugriff (PDF)

Washington's electronic signature act: an anachronism in the new millennium

Washington law review, 2013-06, Vol.88 (2), p.559

Curry, Stephanie

2013

Volltextzugriff (PDF)

Obesity Epidemic: Pharmaceutical Weight Loss

Rhode Island medical journal (2013), 2017-03, Vol.100 (2), p.18-20

Curry, Stephanie A

2017

Volltextzugriff (PDF)

Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a

The Journal of biological chemistry, 2017-04, Vol.292 (15), p.6202-6212

2017

Volltextzugriff (PDF)

Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2

Antimicrobial agents and chemotherapy, 2019-12, Vol.63 (12)

2019

Volltextzugriff (PDF)

Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models

Vaccine, 2023-01, Vol.41 (4), p.903-913

2023

Volltextzugriff (PDF)

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms

Journal of medicinal chemistry, 2017-01, Vol.60 (1), p.290-306

2017

Volltextzugriff (PDF)

Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants

Journal of medicinal chemistry, 2016-11, Vol.59 (22), p.10228-10243

2016

Volltextzugriff (PDF)

Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay

Journal of virological methods, 2008-11, Vol.153 (2), p.156-162

2008

Volltextzugriff (PDF)

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A

Antimicrobial agents and chemotherapy, 2018-11, Vol.62 (11)

2018

Volltextzugriff (PDF)

Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions

Journal of medicinal chemistry, 2018-05, Vol.61 (9), p.3984-4003

2018

Volltextzugriff (PDF)

Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection

Clinical infectious diseases, 2014-12, Vol.59 (12), p.1657-1665

2014

Volltextzugriff (PDF)

Incidence Of Hospital Acquired Anemia

Blood, 2013-11, Vol.122 (21), p.1700-1700

2013

Volltextzugriff (PDF)

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3

Journal of hepatology, 2013-07, Vol.59 (1), p.31-37

2013

Volltextzugriff (PDF)

Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN α-2b using TaqMan mismatch amplification mutation assay

Journal of virological methods, 2008-11, Vol.153 (2), p.156-162

2008

Volltextzugriff (PDF)

Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742

Bioorganic & medicinal chemistry letters, 2016-08, Vol.26 (15), p.3800-3805

2016

Volltextzugriff (PDF)

Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742

Bioorganic & medicinal chemistry letters, 2016-08, Vol.26 (15), p.3414-3420

2016

Volltextzugriff (PDF)

1 – 25 von 140

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(131)
Mit Volltextzugriff
(117)

Publikationsform

Sprache

Englisch
(139)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

Science & Technology
(89)
Life Sciences & Biomedicine
(80)
Humans
(52)
Male
(29)
Female
(24)
Animals
(22)
Biological And Medical Sciences
(21)
Pharmacology & Pharmacy
(19)
Hepacivirus - Drug Effects
(16)
Physical Sciences
(16)
Adult
(15)
Antiviral Agents - Pharmacology
(15)
Chemistry
(15)
Hepatitis C Virus
(14)
Viral Nonstructural Proteins - Antagonists & Inhibitors
(14)
Medical Sciences
(13)
Antiviral Agents - Chemistry
(12)
Chemistry, Medicinal
(12)
Adolescent
(11)
Antiviral Agents
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons

Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons

Functional Analysis of the Chemokine Receptor CCR3 on Airway Epithelial Cells

Regulation of eotaxin gene expression by TNF-alpha and IL-4 through mRNA stabilization: involvement of the RNA-binding protein HuR

A Retrospective Study Investigating the Incidence and Predisposing Factors of Hospital-Acquired Anemia

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors

Abstract #901: Leydig Cell Ovarian Tumor

Mother and child constructions of risk in outdoor play

Washington's electronic signature act: an anachronism in the new millennium

Obesity Epidemic: Pharmaceutical Weight Loss

Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a

Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2

Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms

Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants

Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A

Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions

Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection

Incidence Of Hospital Acquired Anemia

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3

Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN α-2b using TaqMan mismatch amplification mutation assay

Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742

Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742

Suchergebnisse filtern